Many investors appear to be quite bearish on Myriad Genetics, Inc. (MYGN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 48.90% of the float is sold short, suggesting an extreme level of …
Massaro was surprised to discover from his survey that more doctors responded they are aware of Genomic Health's tests over Myriad Genetics, Inc. (NASDAQ: MYGN). The analyst noted ... profile on Genomic Health's stock has "swung to …
Investors found another reason to bid up shares of Myriad Genetics Inc. /quotes/zigman/58124 /quotes/nls/mygn MYGN, which is sole owner of ... hitting a fresh 52-week high. The stock surged last week on third-quarter results that …
Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: …
Mayne said Tikosyn U.S. sales last year were $150 million. Myriad Genetics, Inc. (NASDAQ: MYGN) jumped nearly 5 percent after the company boosted its stock buyback plan by $200 million. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) …
GILEAD SCIENCES, INC. (NASDAQ:GILD), FRESH DEL MONTE PRODUCE INC (NYSE:FDP), MYRIAD GENETICS …
Myriad Genetics Inc. (MYGN) was a big mover last session, as the company saw its shares rise by over 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the …
... GILEAD SCIENCES INC (GILD): Free Stock Analysis Report ALKERMES PLC ORD (ALKS): Free Stock Analysis Report MYRIAD GENETICS INC (MYGN): Free Stock Analysis Report ANI PHARMACEUTICALS INC (ANIP): Free …
The stock carries a Zacks Rank #4 (Sell). As we wait for the company to release second-quarter fiscal 2018 earnings results on Nov 21 2017, the market depicts a bearish picture per the latest preliminary sales update ... Inc. MYGN, …